JP2025509432A - エンタクトゲン心理状態を設計および生成するための治療的組み合わせ、組成物、および方法 - Google Patents

エンタクトゲン心理状態を設計および生成するための治療的組み合わせ、組成物、および方法 Download PDF

Info

Publication number
JP2025509432A
JP2025509432A JP2024553843A JP2024553843A JP2025509432A JP 2025509432 A JP2025509432 A JP 2025509432A JP 2024553843 A JP2024553843 A JP 2024553843A JP 2024553843 A JP2024553843 A JP 2024553843A JP 2025509432 A JP2025509432 A JP 2025509432A
Authority
JP
Japan
Prior art keywords
agent
fold
therapeutic combination
receptor
agonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024553843A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025509432A5 (https=
Inventor
レイ、トーマス
Original Assignee
マインドステイト デザイン ラボズ、インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by マインドステイト デザイン ラボズ、インコーポレイテッド filed Critical マインドステイト デザイン ラボズ、インコーポレイテッド
Publication of JP2025509432A publication Critical patent/JP2025509432A/ja
Publication of JP2025509432A5 publication Critical patent/JP2025509432A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2024553843A 2022-03-09 2023-03-09 エンタクトゲン心理状態を設計および生成するための治療的組み合わせ、組成物、および方法 Pending JP2025509432A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263318369P 2022-03-09 2022-03-09
US63/318,369 2022-03-09
PCT/US2023/014926 WO2023172701A2 (en) 2022-03-09 2023-03-09 Therapeutic combinations, compositions, and methods for designing and producing entactogenic mindstates

Publications (2)

Publication Number Publication Date
JP2025509432A true JP2025509432A (ja) 2025-04-11
JP2025509432A5 JP2025509432A5 (https=) 2026-03-17

Family

ID=87935763

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024553843A Pending JP2025509432A (ja) 2022-03-09 2023-03-09 エンタクトゲン心理状態を設計および生成するための治療的組み合わせ、組成物、および方法

Country Status (11)

Country Link
US (1) US20250177354A1 (https=)
EP (1) EP4489649A2 (https=)
JP (1) JP2025509432A (https=)
KR (1) KR20250011101A (https=)
CN (1) CN119497589A (https=)
AU (1) AU2023232712A1 (https=)
CA (1) CA3245622A1 (https=)
CR (1) CR20240417A (https=)
IL (1) IL315512A (https=)
MX (1) MX2024011043A (https=)
WO (1) WO2023172701A2 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250145285A (ko) * 2024-03-28 2025-10-13 건국대학교 글로컬산학협력단 릴메니딘을 포함하는 정서장애의 예방, 개선 또는 치료용 조성물

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014004676A1 (en) * 2012-06-26 2014-01-03 Ironwood Pharmaceuticals, Inc. Use of faah inhibitors as neuroprotective agents in the cns

Also Published As

Publication number Publication date
CR20240417A (es) 2025-03-04
CA3245622A1 (en) 2023-09-14
US20250177354A1 (en) 2025-06-05
KR20250011101A (ko) 2025-01-21
EP4489649A2 (en) 2025-01-15
IL315512A (en) 2024-11-01
CN119497589A (zh) 2025-02-21
MX2024011043A (es) 2024-12-06
AU2023232712A1 (en) 2024-10-17
WO2023172701A2 (en) 2023-09-14
WO2023172701A3 (en) 2023-11-09

Similar Documents

Publication Publication Date Title
US20240335418A1 (en) Safer psychoactive compositions
WO2022150525A9 (en) Mdma in the treatment of alcohol use disorder
AU2022413759A1 (en) Benzoate salt of 5-methoxy-n,n-dimethyltryptamine
JP2025510914A (ja) 産後うつ病の治療
US20250000881A1 (en) Treatment of treatment resistant depression with psilocybin
CN118267382A (zh) 用于痴呆和神经变性病况中的激越、精神病和认知衰退的环苯扎林治疗
US20240190809A1 (en) Therapeutic aminoindane compounds and compositions
JP2025509432A (ja) エンタクトゲン心理状態を設計および生成するための治療的組み合わせ、組成物、および方法
US20240122895A1 (en) Entactogen-assisted therapy for alcohol use disorder and addiction-related conditions and comorbidities
US20250082607A2 (en) Methods of treating disorders with a psilocybin analog
CA3220228A1 (en) Ketamine in the treatment of behavioural addictions
US12595269B2 (en) Morpholine-like monoamine releasers
KR20260003282A (ko) 주사식 약학적 제형
Zeise Clinical Neuropharmacology
WO2023247665A1 (en) Solid dispersions of psilocybin
US20070225334A1 (en) Methods for treating cognitive and other disorders
WO2026068950A1 (en) Pharmaceutical compositions of 5-meo-dmt for use in the treatment of alcohol use disorders
HK40112834A (zh) 用於痴呆和神经变性病况中的激越、精神病和认知衰退的环苯扎林治疗
Monti et al. Role of zolpidem in the management of primary and comorbid insomnia
Jones Perspectives in Drug Discovery: A Collection of Essays on the Historyand Development of Pharmaceutical Substances
Talavera et al. Rapid Fire Pharmacy Review
CN108778271A (zh) 改善孤独症谱系障碍症状的组合物及使用其改善孤独症谱系障碍症状的方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260309

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260309